Tatyana A Feldman MD

Hematology•Hackensack, NJ

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Physician

Join to View Full Profile

92 2nd StHackensack, NJ 07601
Phone+1 551-996-3033
Fax+1 551-996-0573

Summary

As an attending physician in the Lymphoma Division and director of the T-Cell Lymphoma Program at John Theurer Cancer Center, I am optimistic that current research into intercellular mechanisms can generate effective new therapies for treating this rare type of lymphoma. Immunotherapy, specifically CAR-T 19 cells that are genetically modified to attack lymphoma cells, is an especially exciting new approach.

Tatyana Feldman, M.D., specializes in treating rare T-cell lymphoma using new ty

Dr. Tatyana Feldman is an attending physician in the Lymphoma Division and director of the T-Cell Lymphoma Program at John Theurer Cancer Center. Dr. Feldma...

Education & Training

NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2001
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1999 - 2000
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1995 - 1999
Minsk Medical InstituteClass of 1992

Certifications & Licensure

DC State Medical License 2019 - 2027
NY State Medical License 1998 - 2026
NJ State Medical License 2002 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2016
Top Doctors: New York Metro Area Castle Connolly, 2014
Inside Jersey Top Doctors for Cancer Castle Connolly, 2014
Inside Jersey Magazine Top Doctors Castle Connolly, 2013-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Join now to see all

Clinical Trials

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL Start of enrollment: 2010 Oct 01
Completed
Phase 1, Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Start of enrollment: 2012 Jun 01
Completed
Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2013 May 01
Completed
Phase 1
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Start of enrollment: 2014 Sep 01
Terminated
Phase 2
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Start of enrollment: 2016 Jun 17
COMPLETED
PHASE2
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence Start of enrollment: 2016 Jun 07
Terminated
Phase 1, Phase 2
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma Start of enrollment: 2016 Feb 01
Terminated
Phase 1
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
RECRUITING
A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2017 Sep 05
TERMINATED
PHASE1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
RECRUITING
PHASE1, PHASE2
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies Start of enrollment: 2018 Mar 29
COMPLETED
PHASE1, PHASE2
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type Start of enrollment: 2018 Nov 09
ACTIVE_NOT_RECRUITING
PHASE2
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Start of enrollment: 2019 Mar 12
Completed
Phase 1, Phase 2
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Start of enrollment: 2018 Nov 28
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma Start of enrollment: 2021 Nov 12
RECRUITING
PHASE2
Roles: Contact
A Safety Study of SGN-35T in Adults With Advanced Cancers Start of enrollment: 2024 Feb 29
RECRUITING
PHASE1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Francine M Foss, Youn H Kim, H Miles Prince, Oleg E Akilov, Christiane Querfeld
Journal of Clinical Oncology. 2025-04-01
1 citations
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Pallawi Torka, Tatyana Feldman, Kerry J Savage, Nivetha Ganesan, Esther Drill
Journal of Clinical Oncology. 2025-03-10
Updates on the Biological Heterogeneity of Mantle Cell Lymphoma.
Andrew Ip, Maciej Kabat, Lindsay Fogel, Hassan Alkhatatneh, Jason Voss
Cancers. 2025-02-19

Abstracts/Posters

Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refracto...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
Tatyana A. Feldman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Cost-Effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma.
2019 ASCO Annual Meeting - 6/1/2019
Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

2022 N.J. Top Cancer Doctors Deliver Quality and Compassionate Care, Close to HomeJune 16th, 2022
N.J.’s 2021 Top Cancer Doctors Lead Charge to Help Patients Thrive and Survive After PandemicJune 17th, 2021
John Theurer Cancer Center's Dr. Andre Goy Co-Chairs 21st Annual International Congress on Hematologic MalignanciesFebruary 27th, 2017